

PRECEPTORSHIP PROGRAMME

Breast Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

23-24 SEPTEMBER 2021

Co-Chairs

Nadia Harbeck, Germany

Peter Schmid, United Kingdom

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets
and future perspectives

23-24 September 2021

CO-CHAIRS: Nadia Harbeck, Germany
Peter Schmid, United Kingdom

SPEAKERS: Fatima Cardoso, Portugal
Javier Cortés, Spain
Suzette Delaloge, France
Rebecca Dent, Singapore
David Krug, Germany
Matteo Lambertini, Italy
Shani Paluch-Shimon, Israel
Christian Singer, Austria

LEARNING OBJECTIVES

- To learn about the biology of breast cancer and its implications in the management of this disease
- To learn about the standard of care management of early-stage, locally advanced and metastatic breast cancer in surgery, radiation therapy and systemic therapy
- To understand the crucial role of multidisciplinary care in the management of breast cancer
- To learn about genetic testing and management of BRCA carriers

ACCREDITATION

The programme of this event has been accredited with **7 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

AstraZeneca 

SANOFI GENZYME 

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org

ESMO GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

All timings in the programme are to be considered CEST (Central European Summer Time)

Thursday, 23 September 2021

15:00-15:05 5'	Opening and welcome	
5'	Welcome from ESMO and objectives of the meeting	Nadia Harbeck, DE Peter Schmid, UK
15:05-15:55 50'	Session 1 Early Breast Cancer Luminal Breast Cancer	Chair/Moderator: Peter Schmid, UK
20'	Risk assessment and chemotherapy indications	Nadia Harbeck, DE
20'	Endocrine therapy	Matteo Lambertini, IT
10'	Discussion	Faculty
15:55-16:45 50'	Session 2 Early Breast Cancer TNBC and HER2+	Chair/Moderator: Nadia Harbeck, DE
20'	TNBC	Peter Schmid, UK
20'	HER2+	Javier Cortés, ES
10'	Discussion	Faculty
16:45-17:00	Break	
17:00-17:40 40'	Session 3 Early Breast Cancer Local Regional Therapy	Chair/Moderator: Nadia Harbeck, DE Peter Schmid, UK
15'	Radiotherapy	David Krug, DE
15'	Surgery	Christian Singer, AT
10'	Discussion	Faculty
17:40-18:05 25'	Session 4 Early Breast Cancer Special Treatment Situations	Chair/Moderator: Nadia Harbeck, DE Peter Schmid, UK
15'	Fertility, breast cancer and pregnancy	Matteo Lambertini, IT
10'	Discussion	Faculty
18:05-18:35 30'	Session 5 Metastatic Breast Cancer - Luminal Cancers – part 1	Chair/Moderator: Nadia Harbeck, DE Peter Schmid, UK
20'	Endocrine-based approach: Optimal treatment sequence	Fatima Cardoso, PT
10'	Discussion	Faculty

Friday, 24 September 2021

9:00-9:45 45'	Session 6 Participants Clinical Case Presentations Early Breast Cancer	Chair/Moderator: Nadia Harbeck, DE Peter Schmid, UK
45'	3x15' Clinical Case Presentations and discussions	Faculty
9:45-10:05 20'	Session 7 Metastatic Breast Cancer - Luminal Cancers – part 2	Chair/Moderator: Nadia Harbeck, DE Peter Schmid, UK
10'	Chemotherapy and beyond	Suzette Delalogue, FR
10'	Discussion	Faculty
10:05-10:55 50'	Session 8 Metastatic Breast Cancer - TNBC and HER2	Chair/Moderator: Nadia Harbeck, DE Peter Schmid, UK
20'	TNBC	Rebecca Dent, SG
20'	HER2+	Javier Cortés, ES
10'	Discussion	Faculty
10:55-11:10	Break	
11:10-11:55 45'	Session 9 Participants Clinical Case Presentations Metastatic Breast Cancer	Chair/Moderator: Nadia Harbeck, DE Peter Schmid, UK
45'	3x15' Clinical Case Presentations and discussions	Faculty
11:55-12:20 25'	Session 10 Hereditary Breast Cancer and BRCA	Chair/Moderator: Nadia Harbeck, DE Peter Schmid, UK
15'	Risk assessment, genetic testing and clinical consequences	Shani Paluch-Shimon, IL
10'	Discussion	Faculty
12:20-13:00 40'	Session 11 Metastatic Breast Cancer - Special treatment situations	Chair/Moderator: Nadia Harbeck, DE Peter Schmid, UK
10'	Brain metastases	David Krug, DE
10'	Loco-regional management in de novo metastatic disease	Christian Singer, AT
10'	Oligometastatic disease	Suzette Delalogue, FR
10'	Discussion	Faculty
13:00-13:05 5'	Closing remarks	Nadia Harbeck, DE Peter Schmid, UK

Note: Each slot for clinical case discussion includes short case summary by participant followed by discussion with all.